Abstract
Purpose. Plasmid DNA-based gene therapy involves episomal gene expression and must be given on a chronic basis. Therefore, the purpose of the present study was to examine for toxic side effects of the chronic weekly intravenous administration of plasmid DNA delivered with a nonviral gene transfer method using pegylated immunoliposomes (PIL).
Methods. A 7-kb expression plasmid encoding for rat tyrosine hydroxylase (TH) was encapsulated in PILs targeted with either the murine OX26 monoclonal antibody (MAb) to the rat transferrin receptor (TfR) or with the mouse IgG2a isotype control antibody. Rats were treated with weekly intravenous injections of 5 μg/rat/week of the TH expression plasmid DNA encapsulated in either the TfRMAb-targeted PIL or the mouse IgG2a-targeted PIL for a total period of 6 weeks. A third control group of rats was treated with saline.
Results. The animals treated with either saline, the TfRMAb-PIL, or the mouse IgG2a-PIL had no measurable differences with respect to body weights, 14 serum chemistries, or organ histology of brain, liver, spleen, kidney, heart, or lung. Immunocytochemistry showed no evidence of inflammation in brain. The delivery to brain of the TH expression plasmid was confirmed with Southern blotting.
Conclusions. The PIL nonviral gene transfer method causes no toxic side effects following chronic weekly intravenous administration in rats.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S. Hacein-Bey-Abina, C. von Kalle, M. Schmidt, F. LeDeist, N. Wulffraat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo, and A. Fischer. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-256 (2003).
M. M. McMenamin, A. P. Byrnes, H. M. Charlton, R. S. Coffin, D. S. Latchman, and M. J. A. Wood. A γ34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 83:1225-1237 (1998).
Y. Stallwood, K. D. Fisher, P. H. Gallimore, and V. Mautner. Netralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther. 7:637-643 (2000).
R. A. Dewey, G. Morrissey, C. M. Cowsill, D. Stone, F. Bolognani, N. J. F. Dodd, T. D. Southgate, D. Klatzmann, H. Lassmann, M. G. Castro, and P. R. Lowenstein. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nature Med. 5:1256-1263 (1999).
M. J. A. Wood, H. M. Charlton, K. J. Wood, K. Kajiwara, and A. P. Byrnes. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci. 19:497-501 (1996).
N. Chirmule, K. J. Propert, S. A. Magosin, Y. Qian, R. Qian, and J. M. Wilson. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1574-1583 (1999).
S. M. Zou, P. Erbacher, J. S. Remy, and J. P. Behr. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J. Gene Med. 2:128-134 (2000).
G. Zhang, V. Budker, and J. A. Wolff. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10:1735-1737 (1999).
N. Shi, Y. Zhang, R. J. Boado, C. Zhu, and W. M. Pardridge. Brain-specific expression of an exogenous gene following intravenous administration. Proc. Natl. Acad. Sci. USA 98:12754-12759 (2001).
Y. Zhang, F. Schlachetzki, and W. M. Pardridge. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7:11-18 (2003).
N. Shi and W. M. Pardridge. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA 97:7567-7572 (2000).
Y. Zhang, C. Zhu, and W. M. Pardridge. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6:67-72 (2002).
Y. Zhang, F. Calon, C. Zhu, R. J. Boado, and W. M. Pardridge. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14:1-12 (2003).
N. Shi, R. J. Boado, and W. M. Pardridge. Receptor mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18:1091-1095 (2001).
J. Huwyler, D. Wu, and W. M. Pardridge. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 93:14164-14169 (1996).
D. Duan, P. Sharma, J. Yang, Y. Yue, L. Dudus, Y. Zhang, K. J. Fisher, and J. F. Engelhardt. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virology 72:8568-8577 (1998).
R. J. Boado and W. M. Pardridge. Ten nucleotide cis element in the 3′-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. Molec. Brain Res. 59:109-113 (1998).
J. N. Lozier, G. Csako, T. H. Mondoro, D. M. Krizek, M. E. Metzger, R. Costello, J. G. Vostal, M. E. Rick, R. E. Donahue, and R. A. Morgan. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene Ther. 13:113-124 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Yf., Boado, R.J. & Pardridge, W.M. Absence of Toxicity of Chronic Weekly Intravenous Gene Therapy with Pegylated Immunoliposomes. Pharm Res 20, 1779–1785 (2003). https://doi.org/10.1023/B:PHAM.0000003375.13655.f9
Issue Date:
DOI: https://doi.org/10.1023/B:PHAM.0000003375.13655.f9